AMY SCHWARTZBURG: Open Payments
NPI 1033220967 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,103 in 37 payments from 8 companies in 2025. Trend: 2023 $599 · 2024 $2,328 · 2025 $6,103
Consulting: $4,284Food & beverage: $1,288Travel & lodging: $531
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 14 | $5,445 |
| Amgen Inc. | 10 | $260 |
| Novartis Pharmaceuticals Corporation | 4 | $117 |
| Alexion Pharmaceuticals, Inc. | 2 | $93 |
| TG Therapeutics, Inc. | 3 | $70 |
| Genentech, Inc. | 2 | $51 |
| ABBVIE INC. | 1 | $35 |
| Genentech USA, Inc. | 1 | $32 |
Products named: UPLIZNA, KESIMPTA, BRIUMVI, Ocrevus Zunovo, ULTOMIRIS, BOTOX.
Industry payments across CA — which companies pay providers there.
